

Supplementary Table 2. Mean and SD of daily pegvisomant dose and average IGF-I/ULN by treatment and year since pegvisomant start. All available IGF-I data including data after possible switch of treatment modality.

Years since peg start	Daily pegvisomant dose mg/day, Mean (SD)												
	Combo SSA			Combo DA			Peg mono			Total			
	IGF-I<ULN	IGF-I>ULN	All*	IGF-I<ULN	IGF-I>ULN	All*	IGF-I<ULN	IGF-I>ULN	All*	IGF-I<ULN	IGF-I >ULN	All*	
0	8.9 (4.1)	10.6 (8.4)	10.1 (7.2)	10.2 (2.3)	12.1 (9.1)	11.3 (7.3)	11.6 (5.1)	12.2 (8.2)	12.3 (8.2)	10.7 (4.8)	11.6 (8.3)	11.4 (7.8)	
1	13.4 (7.1)	14.5 (8.9)	13.6 (7.6)	15.1 (6.9)	15.2 (6.9)	15.1 (6.3)	15.6 (7.1)	16.9 (7.4)	15.8 (7.4)	14.9 (7.2)	15.9 (7.9)	15.0 (7.5)	
2	14.0 (7.8)	16.7 (9.3)	14.5 (8.1)	16.2 (5.3)	20.2 (8.1)	17.5 (7.2)	16.3 (7.5)	18.4 (8.2)	16.8 (7.7)	15.6 (7.5)	17.9 (8.7)	16.0 (7.9)	
5	17.9 (11.7)	22.3 (12.0)	17.9 (11.1)	18.8 (7.3)	19.9 (9.1)	19.0 (9.1)	17.6 (8.3)	20.3 (10.0)	18.0 (8.6)	17.6 (9.1)	20.9 (10.6)	18.1 (9.6)	
7	21.3 (17.0)	19.7 (10.9)	19.4 (12.8)	22.0 (6.2)	28.6 (11.7)	21.6 (9.3)	15.9 (6.9)	19.4 (9.5)	18.1 (9.2)	17.6 (10.2)	20.3 (10.5)	18.8 (10.6)	
				IGF-I/ULN Mean (SD)									
0			2.03 (1.15)			1.95 (1.11)			1.87 (0.96)			1.93 (1.04)	
1			1.12 (0.71)			1.13 (0.78)			1.02 (0.62)			1.06 (0.66)	
2			1.06 (0.56)			1.06 (0.58)			0.97 (0.51)			1.00 (0.54)	
5			1.09 (0.64)			1.14 (0.99)			0.91 (0.53)			0.98 (0.52)	
7			1.15 (0.58)			0.99 (0.37)			0.90 (0.49)			0.98 (0.52)	

*Also including patients without IGF-I measurements.